Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraża pisemną zgodę na udział w badaniu.
- •Zdiagnozowano raka piersi (nie leczono wcześniej), potwierdzonego biopsją.
- •Zmiana nowotworowa w piersi jest wystarczająco duża, by ją zmierzyć.
- •Rak piersi jest w początkowym stadium rozwoju (od cT1b do cT3), bez względu na zajęcie węzłów chłonnych.
- •Rak piersi jest pozytywny na białka HER2 i HR (estrogenowe/progesteronowe), a w komórkach guza stwierdzono mutację PIK3CA.
- •Pacjent ma ukończone 18 lat.
- •Ogólny stan zdrowia pacjenta pozwala na udział w badaniu (ECOG 0-1).
- •Serce pacjenta pracuje prawidłowo (potwierdzone EKG i USG serca).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 17, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
KEM Kliniken Essen-Mitte
Essen, Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Germany
DBZ Onkologie
Berlin, Germany
Praxisklinik Krebsheilkunde für Frauen
Berlin, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, Germany
Department of Breast-Center Holweide - Kliniken der Stadt Köln
Cologne, Germany
Städtisches Klinikum Dessau
Dessau, Germany
University Hospital Carl Gustav Carus
Dresden, Germany
Center for Gynecologic Oncology
Düsseldorf, Germany
Frauenklinik des Universitätsklinikums Erlangen
Erlangen, Germany
Klinik für Gynäkologie und Geburtshilfe Agaplesion Markus Krankenhaus
Frankfurt, Germany
SRH Wald-Klinikum Gera GmbH
Gera, Germany
Mammazentrum HH am Krankenhaus Jerusalem
Hamburg, Germany
Klinikum Hanau
Hanau, Germany
DIAKOVERE Henriettenstift Frauenklinik
Hanover, Germany
National Center for Tumor Diseases - University Hospital Heidelberg
Heidelberg, Germany
Elisabeth Krankenhaus Brustzentrum
Kassel, Germany
Praxis für Hämatologie und Onkologie Koblenz and InVo - Institut für Versorgungsforschung in der Onkologie GbR
Koblenz, Germany
University Hospital Mannheim
Mannheim, Germany
University Hospital Gießen and Marburg, Campus Marburg
Marburg, Germany
Media Vita GmbH (MVZ)
Münster, Germany
University Hospital Tübingen
Tübingen, Germany
Department of Gynecology and Obstetrics - University of Ulm
Ulm, Germany
GRN Klinik Weinheim
Weinheim, Germany
Klinikum Worms
Worms, Germany
Helios Universitätsklinikum Wuppertal
Wuppertal, Germany
Università Politecnica delle Marche - Azienda Ospedaliero Universitarià delle Marche
Ancona, Italy
AULSS9 Scaligera - Ospedale Mater Salutis di Legnago
Legnago, Italy
Istituto Europeo di Oncologica
Milan, Italy
Trial contact
Jana Roßney
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.